The data suggested that heterogeneous tumor response to the anti-PLD1 Ab therapy could be attributed to (1) the difference in the expression of PD-L1 protein, (2) the variation in the amount of anti-PD-L1 IgG delivery to tumor cells, (3) the difference in the amount of tumor coagulation inside the tumor, and (4) the difference in the amount of immune cells inside the tumor. This evidence concerns the gene CD274 and neoplasm.